Codes, payment rates, coverage policy, and whose budget it comes from — ctdna mrd assay validation

1. Summary

No HCPCS Level II code could be checked this pass for any product in this domain — this repo's typed hcpcs, payment and coverage connectors each require a local CMS cache file that does not exist on this machine, so every lookup attempted returned unconfirmed for that reason alone. What is established instead, from federal regulation confirmed live via this repo's regulation and policy connectors, is the mechanism that pays the domain's real downstream product — a tumor-informed ctDNA MRD test, not the reference material this domain's dossier centers on: a sufficiently novel, single-source molecular test can be designated an Advanced Diagnostic Laboratory Test (ADLT), and during its initial period Medicare pays that test's own "actual list charge" rather than a fee-schedule amount set by crosswalk or gapfill [1][5]. After that initial period, payment resets to the weighted median of the private payor rates the laboratory itself is legally required to report annually, under penalty of up to $10,000 per day for misreporting [2][3][4]. This is a Medicare Part B mechanism, financed through the Supplementary Medical Insurance structure that governs ordered diagnostic laboratory tests generally, not a device benefit category [6][7]. Whether a payer actually pays that rate is a separate question from the rate existing at all, and two independently retrieved commercial-payer coverage bulletins — described in §5 rather than numbered here — currently answer it in the negative for this domain's namesake test.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

What this environment could check directly, and what it could not

connectors hcpcs, connectors payment and connectors coverage each read from a local CMS cache file (data/hcpcs_level_ii.csv, data/hcpcs_payment_rates.csv, data/medicare_coverage_policies.csv) that is absent on this machine; every code probed this pass returned the connector's own unconfirmed result naming the missing file, never a result about the code itself. Separately, connectors regulation reads live against the eCFR API and does not depend on a local cache, so the eight sections cited below are confirmed live this pass rather than read from a stale copy.

The mechanism that pays the downstream test — ADLT status, CLFS, and PAMA

42 CFR 414.502 defines an Advanced Diagnostic Laboratory Test (ADLT) as a clinical diagnostic laboratory test "offered and furnished only by a single laboratory" that either analyzes multiple DNA/RNA/protein biomarkers with an algorithm yielding a patient-specific prediction, or is FDA cleared or approved; the same section defines "actual list charge" as "the publicly available rate on the first day the new advanced diagnostic laboratory test (ADLT) is obtainable by a patient who is covered by private insurance" [1]. Under 42 CFR 414.522, a new ADLT is paid at that actual list charge for its entire "new ADLT initial period"; only afterward does payment reset to the weighted median established under the general methodology [5]. That general methodology, at 42 CFR 414.507, prices a clinical diagnostic laboratory test (CDLT) — ADLT or not — at "the weighted median for the test," calculated by "arraying the distribution of all private payor rates, weighted by the volume for each payor and each laboratory," and it explicitly caps how far any code's payment can fall in a single year: for 2026 through 2028 a non-ADLT CDLT's rate "may not be reduced by more than" 15 percent per year relative to the prior year's rate [2]. This entire methodology descends from a 2016 final rule implementing section 216 of the Protecting Access to Medicare Act of 2014 (PAMA), which the Federal Register document itself states "revises the Medicare payment system for clinical diagnostic laboratory tests" and "announces an implementation date of January 1, 2018 for the private payor rate-based fee schedule required by PAMA" [3]. For a genuinely new CDLT that is not an ADLT, 42 CFR 414.508 sets the interim path: either "crosswalking" to an existing comparable test's rate, or, where none exists, a two-year "gapfilling" process in which Medicare Administrative Contractors set local amounts in year one and CMS pays the median of those contractor-specific amounts in year two [8]. The laboratory on the other end of all of this carries a reporting duty, not a passive one: 42 CFR 414.504 requires an "applicable laboratory" to report its private payor rates and test volumes — for a new ADLT, within the first two quarters of its initial period and annually thereafter — with the laboratory's own president, CEO or CFO personally certifying the data, and a civil penalty of up to $10,000 per day for a failure to report or a misrepresentation [4].

Whose budget: Medicare Part B, not a device benefit

This entire structure sits under 42 CFR Part 414, which 42 CFR 414.500 states implements "1833(h)(8) of the Act and 1834A of the Act" — the Medicare Part B (Supplementary Medical Insurance) payment provisions of the Social Security Act, not a durable-medical-equipment or drug benefit [7]. Separately, 42 CFR 410.32 — a Part B "conditions of coverage" section — requires that "all diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests must be ordered by the physician who is treating the beneficiary," and that a test not so ordered "are not reasonable and necessary" [6]. Read together, these two sections place a tumor-informed ctDNA MRD test's Medicare payment inside the ordinary Part B physician-ordered diagnostic-testing budget, priced by the CLFS/ADLT mechanism above rather than by any code or allowance specific to a reference-material class.

4. Sources

[1] 42 CFR 414.502, Definitions — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.502 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.502 [federal-registry] [2] 42 CFR 414.507, Payment for clinical diagnostic laboratory tests — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.507 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.507 [federal-registry] [3] Medicare Program; Medicare Clinical Diagnostic Laboratory Tests Payment System — Federal Register, Centers for Medicare & Medicaid Services (published 2016-06-23; accessed 2026-09-01), confirmed live via this repo's policy connector. FR Doc 2016-14531 (81 FR 41036) — https://www.federalregister.gov/documents/2016/06/23/2016-14531/medicare-program-medicare-clinical-diagnostic-laboratory-tests-payment-system [federal-registry] [4] 42 CFR 414.504, Data reporting requirements — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.504 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.504 [federal-registry] [5] 42 CFR 414.522, Payment for new advanced diagnostic laboratory tests — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.522 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.522 [federal-registry] [6] 42 CFR 410.32, Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 410.32 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-410/subpart-B/section-410.32 [federal-registry] [7] 42 CFR 414.500, Basis and scope — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.500 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.500 [federal-registry] [8] 42 CFR 414.508, Payment for a new clinical diagnostic laboratory test — eCFR, retrieved via this repo's regulation connector (issue 2026-08-13; accessed 2026-09-01). 42 CFR 414.508 — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-414/subpart-G/section-414.508 [federal-registry]

5. Sourcing & Gaps

Well established: The ADLT/CLFS payment mechanism — actual-list-charge pricing during a new ADLT's initial period, weighted-median pricing from reported private payor rates afterward, crosswalk/gapfill pricing for a new non-ADLT CDLT, the annual reporting duty with its civil penalty, and the whole structure's basis in Medicare Part B — rests on eight sections of federal regulation and one Federal Register document, each confirmed live this pass against the eCFR and Federal Register APIs via this repo's typed connectors. These are stated plainly, without a sourcing marker, because primary codified law and its own implementing rule are not a directional account of themselves.

Thin: Everything about this domain's actual coverage experience — as opposed to the payment mechanism — rests on exactly two directly-retrieved sources, described below rather than numbered, and both are [single-source] for the specific proposition each supports.

Rescoped from class 3: The unanswerable question here would be "would a payer cover a tumor-informed ctDNA MRD test priced under the ADLT mechanism more readily if its analytical validation rested on a third-party reference panel rather than an in-house control?" — nobody can answer what a payer would do. Its revealed-behaviour twin — does any coverage determination located this pass condition its stance on the specific validation method or reference material used, as opposed to overall clinical evidence — was not answered either way: no coverage text naming a validation methodology or reference-material requirement was located in the two payer bulletins this pass could read, and no Medicare coverage text was retrieved at all (see below). This is recorded as not found, not as a substitute answer to the original question.

Out of scope: CPT and CPT PLA descriptor text, per the scope note above — no descriptor is reproduced anywhere in this report. Non-US coverage or payment policy; no connector in this repo queries one.

Not searched vs. not found — retrieval attempts and their outcomes, stated individually: Not retrieved — the CMS Medicare Coverage Database's own LCD view pages (two candidate LCDs were located by search, titled as MolDX minimal-residual-disease policies, one carrying the identifier L38779), because www.cms.gov returned HTTP 403 on every direct WebFetch attempt; no finding from either LCD is reported anywhere above, and their existence is noted here only as a search-index result, not a retrieved finding. Not retrieved — two CMS CLFS PDF publications (MLN006818 and transmittal MM14312), same HTTP 403 pattern. Not retrieved — the MolDX program manual and a MolDX technical-assessment-form page hosted at dominoapps.palmettogba.com/palmettogba.com, which returned HTTP 503 on two separate attempts. Not retrieved (found but unreadable) — three commercial-payer coverage-policy PDFs (Blue Shield of California, two document versions, and Excellus BCBS), each of which fetched as a compressed/encoded PDF stream that did not render as extractable text in this environment; no finding from any of the three is reported. Retrieved and readable — Aetna's Clinical Policy Bulletin Number 0352 ("Tumor Markers"), whose coding section places Signatera-brand tumor-informed ctDNA MRD testing among interventions it classifies "Experimental, Investigational, or Unproven" for colorectal cancer and several other cancer types, and whose own coding table for this service lists only CPT codes, no HCPCS code — https://www.aetna.com/cpb/medical/data/300_399/0352.html, accessed 2026-09-01. Retrieved and readable — Blue Cross Blue Shield of Mississippi Medical Policy A.2.04.153 ("Tumor-Informed Circulating Tumor DNA Testing for Cancer Management," last review date shown as 2026-01-12), which states verbatim: "Tumor-informed circulating tumor DNA testing (e.g., Signatera) is considered investigational for all indications," and whose own Code Reference section lists only CPT codes (including the PLA number 0340U) with its HCPCS field left empty — https://www.bcbsms.com/policy-search/medical/policy-detail/tumorinformed-circulating-tumor-dna-testing-for-cancer-management, accessed 2026-09-01. Neither Aetna's nor Blue Cross Blue Shield of Mississippi's own policy number matches any of this report's closed identifier forms (PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX, FR Doc number), so neither is numbered in §4; both are recorded here in full, with URL and accessed date, so a later reader can independently re-verify them. Retrieved and readable, also excluded from §4 for the same identifier-format reason — Natera's own press release stating that CMS awarded Signatera (PLA code 0340U) Advanced Diagnostic Laboratory Test status effective 2021-06-18, with an initial CMS-set rate of $3,500 per assay (https://www.natera.com/company/news/natera-awarded-advanced-diagnostic-laboratory-test-adlt-status-for-its-signatera-mrd-test-from-cms-2/, accessed 2026-09-01) [manufacturer], and a health-policy blog's account that CMS's stated CY2025 CLFS price for 0340U moved from an initial $2,919 to a revised $3,920 as of a January 10, 2025 correction, with no CMS transmittal cited by the blog itself (https://www.discoveriesinhealthpolicy.com/2025/01/brief-blog-cms-revises-fee-schedule.html, accessed 2026-09-01), a secondary account of a CMS pricing action rather than a primary CMS document [single-source]. Not searched — Medicaid state-plan coverage, Medicare Advantage plan-level coverage determinations, and UnitedHealthcare's or Cigna's own ctDNA/MRD-specific coverage text (Cigna's policy PDF was located by search but not fetched this pass, given the PDF-extraction failure already observed twice on comparable payer documents).

[inference] The two retrieved commercial-payer determinations, read against the federal payment mechanism in §3, are consistent with (but do not establish) a landscape where the CLFS rate-setting machinery and the coverage decision run on separate tracks: Medicare's ADLT/CLFS mechanism assigned Signatera a market-based rate years ago, while at least two independent commercial payers still classify the same test as experimental, investigational, or unproven. This sentence is the writer's own synthesis of the sourced material above, not a finding either source states.

6. Claim Candidates